Novanta Inc NOVT
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 25, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
3 paragraphs in Risk Factors of the 10-K filed Feb 23, 2026 with nothing like them in the 10-K filed Feb 25, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
On June 16, 2025, an amendment to the UK Medical Devices Regulations became applicable, and it strengthened the post-market surveillance requirements for medical devices in Great Britain. In addition, the MHRA launched a consultation from November 14, 2024 to January 5, 2025 on proposals to update the pre-market requirements for medical devices in Great Britain.
additional tax obligations in countries that choose to adopt new tax requirements such as the proposed Pillar Two rules. Further, such tax law changes may cause our effective tax rate to fluctuate between periods.
In addition, the market price of our common shares may be influenced by the Units. For example, the market price of our common shares could become more volatile and could be depressed by (i) investors’ anticipation of the potential resale in the market of a substantial number of our additional common shares received upon settlement of the purchase contracts that are a component of the Units; (ii) possible sales of our common shares by investors who view the Units as a more attractive means of equity participation in us than owning our common shares; and (iii) hedging or arbitrage trading activity that may develop involving the Units and our common shares.
Paragraphs in the 10-Q filed Nov 9, 2026 that were not in the one before
New in the latest 10-Q
18 paragraphs in the 10-Q filed Nov 9, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
3. Business Combinations 2026 Acquisition On July 23, 2026, the Company completed the acquisition of all of the issued and outstanding limited liability company interests of the parent entity of Riverpoint Medical for total upfront cash consideration of $1,200.6 million, net of cash acquired, subject to customary closing and net working capital adjustments. In addition, the agreement provides for a milestone payment of $250.0 million payable on or before January 8, 2027. Riverpoint Medical is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and cardiovascular surgical applications and is included in the Company’s Medical Solutions Segment. The acquisition of Riverpoint Medical has been accounted for as a business combination under ASC 805, Business Combinations (“ASC 805”). Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company’s consolidated financial statements include results of operations for Riverpoint Medical from the July 23, 2026 acquisition date. Allocation of Purchase Price The purchase price is allocated based upon a valuation of the fair values of assets acquired and liabilities assumed. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The excess of the purchase price over the fair values of the acquired tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The fair values of identifiable intangible assets were based on valuations using an income approach, specifically the multi-period excess earnings method for customer relationships and the relief-from-royalty method for developed technologies and trade name. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including revenue growth rates, customer attrition rates, royalty rates, discount rates, technology obsolescence curves, and EBITDA margins. The Company’s estimates and assumptions in determining the estimated fair value of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information to be obtained with regard to facts and circumstances that existed as of the acquisition date.
Read in the 10-Q
Based upon the Company’s preliminary valuation, the purchase price for Riverpoint Medical was allocated as follows (in thousands): Purchase Price Allocation Cash $5,902 Accounts receivable 25,879 Inventory 27,992 Property, plant and equipment 27,981 Operating lease assets 6,824 Intangible assets 756,000 Goodwill 792,165 Other assets 1,859 Total assets acquired 1,644,602 Accounts payable 3,493 Operating lease liabilities 6,824 Deferred tax liabilities 175,512 Other liabilities 9,571 Total liabilities assumed 195,400 Total assets acquired, net of liabilities assumed 1,449,202 Less: cash acquired 5,902 Total purchase price, net of cash acquired 1,443,300 Less: milestone payment 244,100 Plus: net working capital receivable 1,400 Net cash used for acquisition of business $1,200,600 The purchase price allocation is preliminary as the Company is in the process of collecting additional information. The fair value of intangible assets for Riverpoint Medical is comprised of the following: Estimated Fair Amortization Value Period
Read in the 10-Q
(In thousands) Customer relationships $ 570,000 16 years Developed technologies 170,000 10 years Trade name 16,000 10 years Total $ 756,000 The preliminary purchase price allocation resulted in $756.0 million of identifiable intangible assets and $792.2 million of goodwill. As the Riverpoint Medical acquisition was structured as a stock acquisition for income tax purposes, the goodwill is not deductible. The goodwill recorded represents the anticipated incremental value of future cash flows potentially attributable to: (i) Riverpoint Medical’s ability to grow the business with existing and new customers, including leveraging the Company’s customer base; (ii) Riverpoint Medical’s ability to grow the business through new product introductions; and (iii) cost improvements due to the integration of Riverpoint Medical’s operations into the Company’s existing infrastructure. The operating results of Riverpoint Medical were included in the Company’s results of operations beginning on July 23, 2026. Riverpoint Medical contributed revenues of $32.9 million and a loss before income taxes of $2.3 million to the Company’s operating results for the three and nine months ended October 2, 2026. The loss before income taxes included $10.5 million of amortization of purchased intangible assets and $2.4 million of accretion expense related to the $250.0 million milestone payment due on January 8, 2027. The milestone liability was recorded at its present value of $244.1 million as of the acquisition date, and the $5.9 million discount is being accreted to acquisition and related costs through the payment date.
Read in the 10-Q
annuity contract, which is intended to reduce the plan’s exposure to investment volatility risks.
Read in the 10-Q
The following table provides qualitative information associated with the fair value measurement of the Company’s Level 3 liabilities:
Read in the 10-Q
Show the other 13
Liability October 2, 2026 Fair Value Valuation Technique Unobservable Inputs Percentage Applied
Read in the 10-Q
As of October 2, 2026, estimated amortization expense for each of the five succeeding years and thereafter was as follows (in thousands):
Read in the 10-Q
The Company's effective tax rate of 68.2% for the three months ended October 2, 2026 differs from the Canadian federal and provincial combined statutory tax rate of 29.0% primarily due to significant acquisition-related transaction costs that were not deductible for income tax purposes and a change in the mix of income, most notably in the U.S., resulting from the Riverpoint acquisition. The non-deductible costs reduced pre-tax income for the quarter without a corresponding tax benefit. In addition,
Read in the 10-Q
because the interim tax provision is determined on a year-to-date basis, the effect of these items on the estimated annual effective tax rate was recognized in the current quarter, resulting in an elevated quarterly effective tax rate.
Read in the 10-Q
Acquisition and Related Charges Acquisition costs in connection with business combinations, including advisor, legal, valuation, and other professional or consulting fees, totaled $19.2 million and $28.1 million for the three and nine months ended October 2, 2026, and $1.5 million and $4.4 million for the three and nine months ended September 26, 2025. The majority of acquisition and related costs for the three and nine months ended October 2, 2026 were included in unallocated and the Medical Solutions segment. The majority of acquisition and related costs for the three and nine months ended September 26, 2025 were included in unallocated costs.
Read in the 10-Q
We continue to be affected by volatility and uncertainties in the macroeconomic and geopolitical environment as well as market-driven factors that have impacted the availability, cost, and timely delivery of materials and components. This volatility and uncertainty have been primarily driven by shortages of certain components and materials resulting from increased global demand related to artificial intelligence; export license requirements imposed by the Chinese government on certain rare-earth materials and magnets; inflationary pressures on materials, components, and freight; changes in trade policy, including tariffs; and logistics disruptions resulting from geopolitical conflicts. We continue to work with our suppliers and customers and to pursue sourcing, pricing, and operational actions to mitigate these effects; however, we may not be able to fully offset them.
Read in the 10-Q
Our effective tax rate for the three months ended October 2, 2026 was 68.2%, versus 32.4% for the same period in the prior year. Our effective tax rate of 68.2% for the three months ended October 2, 2026 differs from the Canadian federal and provincial combined statutory tax rate of 29.0% primarily due to significant acquisition-related transaction costs that were not deductible for income tax purposes and a change in the mix of income, most notably in the U.S., resulting from the Riverpoint acquisition. The non-deductible costs reduced pre-tax income for the quarter without a corresponding tax benefit. In addition, because the interim tax provision is determined on a year-to-date basis, the effect of these items on the estimated annual effective tax rate was recognized in the current quarter, resulting in an elevated quarterly effective tax rate.
Read in the 10-Q
vesting of restricted stock units; partially offset by non-deductible compensation, non-deductible transaction-related expenses, and the U.S. BEAT.
Read in the 10-Q
On July 22, 2026, we drew $200.0 million under the 2026 Delayed Draw Term Loan Commitments. In connection with the drawdown, we incurred an additional $0.2 million of deferred financing costs.
Read in the 10-Q
In connection with the acquisition of Riverpoint Medical, the agreement provides for a milestone payment of $250.0 million on or before January 8, 2027. The milestone liability is recorded at its present value within accrued expenses and other current liabilities, which was $246.5 million as of October 2, 2026, and the remaining discount is being accreted to acquisition and related costs through the payment date.
Read in the 10-Q
Market risk
Our exposure to market risk associated with changes in interest rates relates primarily to our borrowings under our Senior Credit Facilities. We had $753.0 million of outstanding variable rate debt as of October 2, 2026. A 100 basis point increase in interest rates at October 2, 2026 would increase our annual pre-tax interest expense by approximately $7.5 million.
Read in the 10-Q
Controls and procedures
During the quarter ended October 2, 2026, we implemented a new financial and operation system at one of our sites as part of a multi-year phased implementation. In connection with this implementation, we modified certain processes and internal controls over financial reporting, and we will continue to do so as additional sites are transitioned to the new system. We have taken steps to preserve the effectiveness of our internal control over financial reporting during the transition.
Read in the 10-Q
On July 23, 2026, we completed the acquisition of Riverpoint Medical. We are integrating Riverpoint Medical into our internal control over financial reporting and expect this to continue over the next twelve months. Management expects to exclude Riverpoint Medical from its assessment of internal control over financial reporting as of December 31, 2026, as permitted by SEC staff guidance.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 9, 2026 against Item 1A of the 10-K filed Feb 23, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:Our risk factors are described in Part I, Item 1A, “Risk Factors”, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Other than the risk factors set forth below, there have been no material changes in our risk factors as included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Read in the 10-Q
Show the other 4
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 23, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 25, 2025
Where each one is used
- fourth amended: As of December 31, 2025, we had outstanding debt of $149.0 million under our fourth amended and restated senior secured credit agreement (as amended, the “Fourth Amended and Restated Credit Agreement”), $850.0 million of additional borrowing capacity available under the revolving credit facility, and $110.6 million...
- artificial intelligence: Technology requirements in our markets are constantly changing. We must continually introduce new products that meet evolving customer needs. Our ability to grow depends on the successful development, introduction and market acceptance of new or enhanced products that address our customers’ requirements. Developing...
- czech republic: We assemble our products at our facilities in the U.S., the U.K., Germany, Czech Republic and China. Each of our products is typically manufactured in a single manufacturing location. If our production activities at any of our manufacturing facilities were disrupted, including by mandatory power consumption...
- publicly accessible: Under the UK Medical Devices Regulations, in order to be lawfully placed on the Great Britain market, Class I (non-sterile, non-measuring or non-re-useable) medical devices need to be self-certified, in accordance with United Kingdom Conformity Assessment (“UKCA”), and other medical devices need to be “UKCA”...
- accessible database: Under the UK Medical Devices Regulations, in order to be lawfully placed on the Great Britain market, Class I (non-sterile, non-measuring or non-re-useable) medical devices need to be self-certified, in accordance with United Kingdom Conformity Assessment (“UKCA”), and other medical devices need to be “UKCA”...
- iso certification: From time to time, legislation is drafted and introduced in the U.S. that could significantly change the statutory provisions governing the regulation of medical devices. In addition, the FDA may change its policies, adopt additional regulations or revise existing regulations, or take other actions, which may...
- amortizing notes: As of December 31, 2025, we had outstanding debt of $149.0 million under our fourth amended and restated senior secured credit agreement (as amended, the “Fourth Amended and Restated Credit Agreement”), $850.0 million of additional borrowing capacity available under the revolving credit facility, and $110.6 million...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
1 paragraph of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NOVT/export.csv") into a cell.